寡转移性肾细胞癌立体定向放疗的预测因素:一项回顾性研究
该回顾性研究分析了2007年11月至2022年7月间接受序贯立体定向消融放疗(SAbR)的153例寡转移性肾细胞癌(omRCC)患者,共337处转移灶,中位随访27个月。中位总生存期(OS)为61.3个月,中位无进展生存期(PFS)为32个月,3年局部控制(LC)率为98%,≥3级毒性发生率为1.3%。骨、脑转移及诊断时转移灶数量是PFS的预测因素。
要点
- 中位OS为61.3个月,中位PFS为32个月,3年LC率为98%,≥3级毒性率为1.3%。
- 骨转移和脑转移患者PFS较低,诊断时转移灶数量是PFS预测因素。
- 对选定患者,SAbR可有效控制omRCC超过2年并延迟系统治疗而不影响结局。
核心结论
- 对选定患者,SAbR可有效控制omRCC超过2年,并能延迟系统治疗而不损害患者结局。
- 骨转移、脑转移及诊断时转移灶数量增加是接受序贯SAbR的omRCC患者的不良预测因素,这些患者可能从 upfront 系统治疗中获益。
研究设计与样本
- 回顾性研究,纳入2007年11月至2022年7月接受序贯SAbR的omRCC患者,转移部位最多5处。
- 共分析153例患者,337处转移灶,中位随访27个月。
- 分析OS、PFS、LC和毒性;采用单变量分析和基于Cox比例风险(CPH)模型的机器学习方法分析PFS预测因素。
主要发现
- 中位OS为61.3个月,中位PFS为32个月。
- ≥3级毒性发生率为1.3%,3年LC率为98%。
- 单变量分析显示骨转移和脑转移患者PFS较低。
- 与历史对照相比,本队列一线系统治疗的延迟起始PFS未受损害。
- CPH模型发现骨转移、脑转移和诊断时转移灶数量是PFS的预测因素,C-index为0.66,1年AUC为0.68。
临床怎么用
- 作者认为,对选定患者,SAbR可有效控制omRCC超过2年并延迟系统治疗而不损害结局。
- 作者认为,骨转移、脑转移及诊断时转移灶数量增加是接受序贯SAbR的omRCC患者的不良预测因素,这些患者可能从 upfront 系统治疗中获益。
局限性
- 原文为回顾性研究。
- 需要前瞻性研究来验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Stereotactic ablative radiotherapy (SAbR) has shown promise in controlling oligometastatic renal cell carcinoma (omRCC). Careful patient selection is critical, and yet the selection criteria remain unknown for patients who will not be harmed by delayed systemic therapy using SAbR. Here, we analyzed long-term follow-up of omRCC patients treated with SAbR to derive the predictors of survival benefit. METHODS: We retrospectively reviewed patients with up to five omRCC sites treated with sequential SAbR from November 2007 to July 2022. Overall survival (OS), progression-free survival (PFS), local control (LC), and toxicity were analyzed. The predictors of PFS were analyzed using a univariate analysis and a Cox proportional hazard (CPH) model-based machine learning approach. KEY FINDINGS AND LIMITATIONS: We analyzed 153 patients who underwent SAbR to 337 metastases with a median follow-up of 27 mo. The median OS and PFS were 61.3 and 32 mo, respectively. The rate of grade ≥3 toxicity was 1.3%, and the 3-yr rate of LC was 98%. Patients with bone and brain metastases had lower PFS on the univariate analysis. When compared with historical controls, the delayed-onset PFS with first-line systemic therapy in this cohort was not compromised. The CPH model found bone, brain, and number of metastases at diagnosis to be the predictors of PFS, with a C-index of 0.66 and 1-yr area under the curve of 0.68. CONCLUSIONS AND CLINICAL IMPLICATIONS: For selected patients, SAbR is effective in controlling omRCC for >2 yr and can delay systemic therapy without compromising patient outcome. Bone and brain metastases, as well as an increasing number of metastases are poor predictive factors for omRCC patients treated with sequential SAbR who may benefit from upfront systemic therapy. Prospective studies are required to verify these findings.
引用
- Yen A, Tang S, Christie A, et al. Predictive Factors for Oligometastatic Renal Cell Carcinoma Treated with Stereotactic Radiation: A Retrospective Study. Eur Urol Oncol. 2025. PMID: 40158924. doi:10.1016/j.euo.2025.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。